- Trials with a EudraCT protocol (17)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
17 result(s) found for: Germ Cells.
Displaying page 1 of 1.
EudraCT Number: 2017-000589-31 | Sponsor Protocol Number: NEMESIS | Start Date*: 2018-02-02 | ||||||||||||||||
Sponsor Name:SOCIETà CAMPANA DI IMMUNOTERAPIA ONCOLOGICA | ||||||||||||||||||
Full Title: multi stage phase II trial of Nivolumab (an anti –PD-1) in patients with platinum resistant Mismatch Repair deficient germinal cells tumours | ||||||||||||||||||
Medical condition: patients with platinum resistant Mismatch Repair deficient germinal cells tumours | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004141-17 | Sponsor Protocol Number: | Start Date*: 2020-08-07 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Children's Oncology Group | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Ovarian, Testicular, or Extragonadal germ cell tumours | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001688-35 | Sponsor Protocol Number: APACHE | Start Date*: 2016-09-09 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab, alone or in combination with Tremelimumab, in patients with advanced and relapsed germ cell tumors | |||||||||||||
Medical condition: Advanced and relapsed germ cell tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004458-27 | Sponsor Protocol Number: Krypto-3 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: Optimizing the fertility potential of bilateral cryptorchidism by treatment with adjuvant kryptocur. | |||||||||||||
Medical condition: Cryptorchidism | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001784-36 | Sponsor Protocol Number: PAED-201601 | Start Date*: 2019-08-12 |
Sponsor Name:Rheinische Friedrich-Wilhelms-Universität Bonn | ||
Full Title: Multicentre prospective trial for extracranial malignant germ cell tumours including a randomized comparison of Carboplatin and Cisplatin | ||
Medical condition: Extracranial germ cell tumours of any malignant histology, primary site and stage | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) AT (Ongoing) NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002260-14 | Sponsor Protocol Number: UC-0105/1612 | Start Date*: 2017-04-03 |
Sponsor Name:UNICANCER | ||
Full Title: Secured access to pembrolizumab for adult patients with selected rare cancer types. | ||
Medical condition: Patients with unresectable locally advanced or metastatic, rare soft tissue sarcoma, visceral sarcoma, or bone sarcoma, rare ovarian cancer, primary central nervous system lymphomas (PCNSL), rare t... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002805-36 | Sponsor Protocol Number: ENGOT-OV30/NSGO | Start Date*: 2017-10-23 | |||||||||||
Sponsor Name:NSGO | |||||||||||||
Full Title: NSGO-OV-UMB1; ENGOT-OV30: A phase II umbrella trial in patients with relapsed ovarian cancer. | |||||||||||||
Medical condition: Ovarian cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) FI (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005594-21 | Sponsor Protocol Number: ADP-04511 | Start Date*: 2016-08-18 | |||||||||||
Sponsor Name:Adaptimmune LLC | |||||||||||||
Full Title: A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ Patients with Synovial Sarcoma | |||||||||||||
Medical condition: Unresectable, metastatic or recurrent synovial sarcomas | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003176-16 | Sponsor Protocol Number: ADP-0055-003/GOG-3084 | Start Date*: 2023-05-03 |
Sponsor Name:Adaptimmune LLC | ||
Full Title: A PHASE 2, OPEN-LABEL, RANDOMIZED, NON-COMPARATIVE CLINICAL TRIAL OF ADP-A2M4CD8 MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH RECURRENT OVARIAN CANCERS (SURPASS-3 STUDY/ GOG-3084) | ||
Medical condition: Recurrent ovarian cancer positive for MAGE-A4 in human leukocyte antigen (HLA)-A2+ subjects | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-009154-25 | Sponsor Protocol Number: omalizumab/2009/01 | Start Date*: 2009-07-07 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: The effect of a humanised monoclonal anti-IgE antibody (omalizumab) on disease control and bronchial mucosal inflammation in non-atopic (“intrinsic”) asthma | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004899-19 | Sponsor Protocol Number: UC-BCG-1911 | Start Date*: 2020-06-09 |
Sponsor Name:UNICANCER | ||
Full Title: Adjuvant PalbOciclib + LetrOzole combination for hormone receptor positive / HER2-negative, Intermediate Risk breast cancer | ||
Medical condition: Hormone receptor (HR) positive / HER2-negative localized breast cancer in menopausal patient considered as having an intermediate risk of relapse. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-004190-12 | Sponsor Protocol Number: MK8808-003 | Start Date*: 2013-03-29 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of MK-8808 versus MabThera™ in Patients with Advanced CD20-Positive Follicular Lymphoma. | |||||||||||||
Medical condition: Previously untreated patients with CD20-positive follicular lymphoma, Grade 1, 2 or 3a according to the WHO 2008 classification system. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000269-30 | Sponsor Protocol Number: MO29518 | Start Date*: 2015-08-26 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: AN OPEN-LABEL, MULTICOHORT, PHASE II STUDY OF ATEZOLIZUMAB IN ADVANCED SOLID TUMORS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Patients with histologically documented advanced solid tumors that meet protocol-defined cohort specifications, have progressed following at least one line of prior systemic anticancer therapy, or ... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) NL (Completed) IE (Completed) AT (Completed) ES (Completed) FI (Completed) GB (Completed) DK (Completed) PL (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003335-29 | Sponsor Protocol Number: SIOPEATRT01 | Start Date*: 2021-04-15 |
Sponsor Name:German Pediatric Oncology Group, GPOH gGmbH | ||
Full Title: An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT) including A randomized phase III study evaluating the non-inferiority of three courses of hig... | ||
Medical condition: atypical teratoid/rhabdoid tumours (ATRT) | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) NO (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001989-10 | Sponsor Protocol Number: CPI0610-04 | Start Date*: 2021-01-08 | ||||||||||||||||||||||||||
Sponsor Name:Constellation Pharmaceuticals, Inc. | ||||||||||||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients | ||||||||||||||||||||||||||||
Medical condition: Myelofibrosis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Ongoing) HU (Ongoing) DE (Ongoing) AT (Ongoing) PL (Ongoing) CZ (Ongoing) NL (Ongoing) BE (Ongoing) IT (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004323-20 | Sponsor Protocol Number: BNT211-01 | Start Date*: 2020-06-30 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:BioNTech Cell & Gene Therapies GmbH | |||||||||||||||||||||||||||||||||||||||||||
Full Title: Phase 1/2a, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: CLDN6-positive relapsed or refractory advanced solid tumors | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Ongoing) NL (Ongoing) SE (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002464-27 | Sponsor Protocol Number: IEOS707/412 | Start Date*: 2013-06-26 | ||||||||||||||||||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | ||||||||||||||||||||||||||||
Full Title: Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients with solid tumors metastatic or relapsed, resistant/refractory to conventional therapy, using HLA-identical related donors or H... | ||||||||||||||||||||||||||||
Medical condition: solid tumors metastatic or relapsed, resistant/refractory to conventional therapy | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.